Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates

Infectious Diseases and Therapy

Volumn 4, Issue 2, 2015, Pages 187-198

  Stockmann, Chris ^a   Hersh, Adam L ^a   Roberts, Jessica K ^a   Bhongsatiern, Jiraganya ^b   Korgenski, Ernest K ^c   Spigarelli, Michael G ^a   Sherwin, Catherine M T ^a   Frymoyer, Adam ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Infectious diseases; MRSA; Neonates; Pharmacokinetics; Staphylococcus aureus; Vancomycin

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HUMAN; IMMUNOASSAY; INFANT; MALE; MEASUREMENT ACCURACY; PERFORMANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION STUDY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84977126023     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-015-0067-9     Document Type: Article

References (21)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis An Off Pub Infect Dis Soc Am. 2011;52(3):e18–55.
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. New Eng J Med. 2003;349(12):1157–67.
3. Stockmann C, Roberts JK, Yu T, et al. Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Rev Anti Infect Ther. 2014;12(11):1371–88.
4. Ringenberg T, Robinson C, Meyers R, et al. Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients. Pediat Infect Dis J; 2015; (Epub ahead of print).
5. Vandendriessche A, Allegaert K, Cossey V, Naulaers G, Saegeman V, Smits A. Prospective validation of neonatal vancomycin dosing regimens is urgently needed. Curr Ther Res Clin Exp. 2014;76:51–7.
6. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Sem Fetal Neo Med. 2013;18(1):28–34.
7. Frymoyer A, Hersh AL, El-Komy MH, et al. Association Between Vancomycin Trough Concentration and AUC in Neonates. Antimicr Agents Chemother; 2014.
8. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26(3):294–305.
9. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res Int J. 1972;5(5):411–59.
10. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71(12):1344–8.
11. Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetic decision making. Clin Pharm. 1984;3(5):525–30.
12. Srivastava T, Alon US, Althahabi R, Garg U. Impact of standardization of creatinine methodology on the assessment of glomerular filtration rate in children. Pediatr Res. 2009;65(1):113–6.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.
14. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–49.
15. Brendel K, Comets E, Laffont C, Mentre F. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn. 2010;37(1):49–65.
16. US FDA. Guidance for industry: population pharmacokinetics [online]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf. Accessed 18 Sep 2014.
17. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221–34.
18. Lee JY, Garnett CE, Gobburu JV, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet. 2011;50(10):627–35.
19. Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309–16.
20. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Annal Pharmacother. 2011;45(6):757–63.
21. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis An Off Pub Infect Dis Soc Am. 2009;49(3):325–7.